Pending a partnership or other funding, Vaxart expects to conduct a Phase 2b safety and immunogenicity study that could potentially begin as early as the second half of 2025, followed by an End of ...

(Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric ...

General and Administrative (G&A) expenses: G&A expenses totaled $5.2 million for the second quarter of 2025. These expenses include $3.1 million of personnel-related costs, including $1.4 million of ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today reported financial results for the second quarter ended June 30 ...

In July 2025, the FDA approved Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy (DCM). The ...

In June, the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on ...

Tenax remains on track to initiate a second registrational Phase 3 study of TNX-103, LEVEL-2, in patients with PH-HFpEF this year. The protocol for LEVEL-2 has been finalized, and the study will have ...

Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates ...

In 2025, CrazyBulk is redefining building muscle after 50 by boosting healthy testosterone levels, improving mTOR ...

Revenue for the second quarter of 2025 was $7.7 million, a decrease of 9% vs. the second quarter of 2024. Global recurring revenue of $5.1 million declined 4% YoY and equipment revenue of $2.5 million ...

Total revenues were $15.3 million for the second quarter of 2025 compared to $8.0 million in the second quarter of 2024. The increase was primarily due to variability in customers’ manufacturing ...

Revenues for the second quarter of 2025 were $2.7 million, increasing 26% compared to the first quarter of 2025. Hyperfine, Inc. sold 8 commercial Swoop® systems in the second quarter of 2025, up from ...